VCEL Vericel Corp
- Stocks
- Healthcare
- NASDAQ: VCEL
Price (delayed)
$40.39
Market cap
$2.03B
P/E Ratio
807.8
Dividend/share
N/A
EPS
$0.05
Enterprise value
$2.05B
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured
Highlights
The stock's P/E is 50% less than its last 4 quarters average of 1586.4
The equity rose by 26% year-on-year
The quick ratio has increased by 17% since the previous quarter but it has declined by 6% year-on-year
The EPS has plunged by 76% from the previous quarter
The net income has shrunk by 71% QoQ
Key stats
What are the main financial stats of VCEL
Market
Valuations
Earnings
Shares outstanding
50.34M
Market cap
$2.03B
Enterprise value
$2.05B
Price to earnings (P/E)
807.8
Price to book (P/B)
6.83
Price to sales (P/S)
8.45
EV/EBIT
548.83
EV/EBITDA
122.08
EV/Sales
8.6
Revenue
$238.54M
Gross profit
$173.03M
Operating income
-$2.81M
Net income
$2.98M
EBIT
$3.74M
EBITDA
$16.81M
Free cash flow
-$6.61M
Per share
Balance sheet
Liquidity
EPS
$0.05
EPS diluted
$0.04
Free cash flow per share
-$0.13
Book value per share
$5.91
Revenue per share
$4.78
TBVPS
$8.39
Total assets
$424.59M
Total liabilities
$129.1M
Debt
$98.97M
Equity
$295.49M
Working capital
$158.19M
Debt to equity
0.33
Current ratio
5.01
Quick ratio
4.36
Net debt/EBITDA
1.15
Margins
Efficiency
Dividend
EBITDA margin
7%
Gross margin
72.5%
Net margin
1.2%
Operating margin
-1.2%
Return on assets
0.7%
Return on equity
1.1%
Return on invested capital
1%
Return on capital employed
1%
Return on sales
1.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VCEL stock price
How has the Vericel stock price performed over time
Intraday
1.33%
1 week
0.1%
1 month
-5.08%
1 year
-21.24%
YTD
-26.44%
QTD
-5.08%
Financial performance
How have Vericel's revenue and profit performed over time
Revenue
$238.54M
Gross profit
$173.03M
Operating income
-$2.81M
Net income
$2.98M
Gross margin
72.5%
Net margin
1.2%
Vericel's operating margin has plunged by 163% from the previous quarter but it has increased by 33% YoY
Vericel's operating income has shrunk by 162% QoQ but it has increased by 25% YoY
The net margin has shrunk by 73% QoQ
The net income has shrunk by 71% QoQ
Price vs fundamentals
How does VCEL's price correlate with its fundamentals
Growth
What is Vericel's growth rate over time
Valuation
What is Vericel stock price valuation
P/E
807.8
P/B
6.83
P/S
8.45
EV/EBIT
548.83
EV/EBITDA
122.08
EV/Sales
8.6
The EPS has plunged by 76% from the previous quarter
The stock's P/E is 50% less than its last 4 quarters average of 1586.4
VCEL's price to book (P/B) is 31% lower than its 5-year quarterly average of 9.7 and 21% lower than its last 4 quarters average of 8.5
The equity rose by 26% year-on-year
VCEL's price to sales (P/S) is 21% lower than its 5-year quarterly average of 10.6 and 17% lower than its last 4 quarters average of 10.0
The revenue has grown by 15% YoY
Efficiency
How efficient is Vericel business performance
The ROS has soared by 78% YoY but it has plunged by 66% from the previous quarter
Vericel's return on assets has shrunk by 74% QoQ
VCEL's ROE has plunged by 73% from the previous quarter
The ROIC has dropped by 68% since the previous quarter but it has soared by 67% year-on-year
Dividends
What is VCEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VCEL.
Financial health
How did Vericel financials performed over time
The total assets has increased by 19% YoY
VCEL's current ratio is up by 18% since the previous quarter but it is down by 3.7% year-on-year
The debt is 67% lower than the equity
The equity rose by 26% year-on-year
Vericel's debt to equity has decreased by 15% YoY and by 2.9% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.